millennials
AstraZeneca opens new global strategic R&D centre in US
The new centre will be home to nearly 2,000 world-class researchers and scientists
Pharma leadership strategies for talent, AI adoption, and continuous learning
In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous...
AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics
This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments
Patients are telling the truth — just not to you
Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.
AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer
The results from a global phase 3 trial show the longest survival data ever reported in this setting
AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer
This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
Cases of skin cancer set to reach 263,000 in 2035 according to new report
The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe
AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma
Asthma affects over 360 million people worldwide, including over 40 million people in Europe
AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical
The company will gain a novel oral treatment for lung cancer
Boehringer Ingelheim’s Jascayd approved by MHRA for idiopathic pulmonary fibrosis
This is the first treatment breakthrough in pulmonary fibrosis in over a decade
Older trial participants reject bad design, not technology
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.